Stem Cell Club — Header Component
⏳ Standard price $2,499 → $1,999 locked in for life during our current promotion. Book now →
(435) 281-2999 Book Free Consult
Patient Education

5 Million Live Cells Beats 250 Million Dead Ones. Every Time.

Every week, someone asks me the same question: "How many stem cells am I getting?" It's the wrong question — and the entire industry is built around making sure you ask it.

Here's what you should actually be asking, and why a small number of living umbilical cord stem cells will do far more for your body than a syringe full of dead ones.

>70%
Viability Standard
<10%
Most Overseas Products
0
What Dead Cells Do

The Question Everyone Asks — and Why It's Wrong

Walk into ten different stem cell clinics and ask about their product. Nine of them will lead with a number. "We give you 100 million cells. We give you 250 million. We give you 300 million."

The bigger the number, the better the deal sounds. It's a clean, simple pitch — and it's almost completely meaningless.

Here's why: a "cell count" on a vial label tells you how much material is in the vial. It does not tell you whether those cells are alive. It does not tell you whether they're functional. It does not tell you whether they're actually mesenchymal stem cells at all, or just nucleated debris padded with red blood cells, white blood cells, and broken cellular fragments.

"How many cells am I getting?"
"How many live, functional cells am I getting post-thaw?"

That single change in wording separates clinics that source honestly from clinics that don't. It's the question the cell count marketers don't want you to learn.

The Math Nobody in This Industry Wants You to Do

Mesenchymal stem cells (MSCs) have one property that makes the viability conversation matter so much: they replicate. Under the right conditions, MSCs can double in number roughly every 24 to 48 hours.

That's the whole game. Live cells don't just sit there — they expand, signal, recruit, and multiply. Dead cells do none of that. Ever. So let's actually run the numbers.

Live Cells vs. Dead Cells: The Real Math
What happens after the injection
5M Live Cells (High Viability)
5,000,000
↓ doubles ↓ doubles ↓ doubles
40,000,000+
Active, signaling cells
40M Dead Cells (Low Viability)
40,000,000
↓ cleared as debris ↓
0
Plus potential inflammation

Illustrative example based on published MSC doubling rates in optimal conditions. Individual in-vivo response varies; biological behavior is influenced by host environment, route of administration, and patient factors.

A small population of living umbilical cord stem cells does more biological work than a massive population of dead ones — not because of some marketing math, but because that's how biology functions. Cells communicate. Cells release growth factors. Cells modulate inflammation. Cells replicate.

Cellular debris does the opposite. Your immune system sees dead material as something to clear out, which can trigger inflammation — the exact thing regenerative therapy is supposed to help calm down.

"More cells" doesn't mean better outcomes. More live cells does.
— The premise that built The Stem Cell Club

Why Most Products Lose Their Cells Before You Get Them

Almost every stem cell product on the market is cryopreserved — frozen for shipping and storage. Freezing keeps cells viable for transport, but the freeze-thaw cycle is rough on cells. Done well, most of the cells survive. Done poorly, almost none do.

This is where the gap between honest and dishonest sourcing shows up most clearly:

01

Counted Before Freezing

Many suppliers report cell counts from before cryopreservation. They never re-count after thawing. The number on the label may bear little resemblance to what reaches your bloodstream.

02

Shipped on Dry Ice

Cells in transit need carefully controlled conditions. Dry ice without validated thaw protocols can damage cellular structure. The cells arrive technically present, but functionally dead.

03

Padded with Debris

"300 million cells" often includes red blood cells, white blood cells, dead cellular fragments, and other non-stem-cell material. The actual viable MSC count can be a small fraction of that.

04

No Independent Testing

Flow cytometry — the gold-standard test for cell viability and identity — is rarely done on low-grade product. Without it, every viability claim is essentially a guess.

Industry data suggests that many regenerative products — particularly those sourced overseas — contain less than 10% viable cells after thawing. That means 90% or more of what's being injected is dead material. You can pay a premium for that, but you're not getting a premium therapy.

What the Gold Standard Actually Looks Like

A high-quality umbilical cord MSC product, sourced from a reputable U.S. laboratory operating under CLIA and FDA oversight, looks fundamentally different on paper than what you'll get from a generic overseas supplier.

What to Check Quality Product Low-Quality Product
Post-Thaw Viability >70% verified via flow cytometry, after thawing Often <10%; verification missing or pre-freeze only
Cell Identity (Markers) CD90+, CD73+, CD44+ documented per lot No marker testing; identity assumed, not verified
Lab Origin U.S.-based, CLIA-certified, FDA-registered facility Overseas or unregistered; no regulatory oversight
Quality Control Lot-based release testing with documented results Vague protocols; refusal to share testing data
Donor Screening Full infectious disease panel; ethical sourcing documented Incomplete or unclear source information
Functional Activity Immunomodulatory function preserved after thaw No data on functional activity

The difference between these two columns is the difference between an investment in your health and an expensive disappointment.

What to Ask Your Provider Before You Pay

Before you spend $10,000, $15,000, or $25,000 on a stem cell treatment — or even $2,000 — ask these questions. If a provider can't answer them, that answer is your answer.

The Five Questions That Separate Real From Fake

  • What is the post-thaw viability of the cells I'll receive? A real number should be available. "Over 70%" is the threshold to look for. Pre-freeze viability doesn't count.
  • Where is the laboratory located, and is it CLIA-certified and FDA-registered? The answer should be the U.S., and they should be able to name the facility.
  • Can I see flow cytometry data and the certificate of analysis for the lot? Reputable suppliers issue lot-specific documentation. If the answer is "we don't share that," walk away.
  • What cell surface markers have been verified? CD90+, CD73+, CD44+ confirm you're getting mesenchymal stem cells — not a soup of random nucleated material.
  • How are the cells handled from thaw to administration? Time, temperature, and handling between thaw and injection matter. A clinic that can walk you through their protocol step by step has nothing to hide.

Transparency is the single best signal of quality in this industry. Suppliers who can verify what they're selling will. Suppliers who can't, won't — and they'll usually try to redirect the conversation to the big shiny cell count instead.

How We Source at The Stem Cell Club

The reason we exist is the gap between what most patients pay and what most patients actually get. Our model is built around three commitments:

1. U.S. labs, every time.

Our umbilical cord MSC product is sourced directly from a CLIA-certified, FDA-registered U.S. laboratory. No overseas relabeling. No broker chain that adds cost and erodes verification.

2. Verified post-thaw viability.

Our supplier confirms viability greater than 70% post-thaw using flow cytometry, with documented cell surface marker expression (CD90+, CD73+, CD44+) per lot. That's the data that should be available for any product you're considering — not just ours.

3. Radical price transparency.

Standard industry pricing for high-viability umbilical cord MSC therapy runs $10,000 to $25,000 per treatment. By sourcing direct and removing broker markups, we offer the same caliber of product at $1,999 (promotional pricing) / $2,499 (regular). The cells are the same. The math is just different when you cut out the middle.

Frequently Asked Questions

If cell count doesn't matter, why do clinics advertise it?
Because big numbers sell. A "300 million cell" headline is easier to market than a conversation about flow cytometry, cell surface markers, and post-thaw viability. The industry has trained patients to compare clinics by raw cell count because it's the only metric that consistently sounds impressive — even when the underlying product is mostly dead material. The clinics that lead with viability are usually the ones that have something real to show.
What is post-thaw viability, exactly?
Post-thaw viability is the percentage of cells that are still alive and functional after the product has been thawed from cryopreservation. It's measured using a technique called flow cytometry, which analyzes thousands of individual cells one at a time. A product with 70% post-thaw viability means that out of every 100 cells in the vial, 70 are alive and capable of biological activity when they reach you.
Why do stem cells need to be frozen at all?
Living cells have a short shelf life outside the body. Cryopreservation — freezing in a specialized cryoprotectant solution — pauses cellular activity and lets cells be stored and shipped without losing viability, as long as the freeze-thaw process is done correctly. Done well, the vast majority of cells survive. Done poorly, almost none do. This is why how a supplier freezes, ships, and thaws matters as much as the cells themselves.
Can dead cells cause harm?
Dead cellular material is generally cleared by the immune system as debris. In the process of clearing it, the body can mount an inflammatory response — which is the opposite of what regenerative therapy is intended to do. Injecting large quantities of dead cells doesn't just fail to help; it can potentially work against the very goal of the treatment.
Do live stem cells really keep multiplying after they're injected?
Mesenchymal stem cells have well-documented proliferative capacity in laboratory conditions, doubling roughly every 24 to 48 hours under optimal circumstances. In the body, behavior is more complex — cells respond to the local environment, signaling cues, and host factors. The main therapeutic action of MSCs is paracrine signaling (releasing growth factors, cytokines, and exosomes that influence surrounding tissue), with some proliferation alongside. Either way, the prerequisite is the same: the cells have to be alive.
How can I tell if a clinic's claims are real?
Ask for the lot-specific certificate of analysis from the laboratory. A real C of A will list post-thaw viability percentage, cell surface marker confirmation (CD90+, CD73+, CD44+), and donor screening results. Clinics with quality product can produce this paperwork. Clinics without it usually deflect — claiming proprietary information, citing the supplier, or simply not responding. Documentation is the dividing line.
How much should high-viability stem cell therapy actually cost?
The product itself, sourced directly from a U.S. CLIA-certified lab, is not the cost driver most patients assume. Industry pricing of $10,000 to $25,000 per treatment reflects layered markups across brokers, distributors, and clinic margins — not the underlying biology. The Stem Cell Club's model removes those layers, offering treatment at $1,999 promotional / $2,499 regular. The product caliber is independent of what you're charged.

Ask the Right Question. Get the Right Answer.

If you're considering stem cell therapy — with us or anyone else — the question isn't how many cells. It's how many live cells. We're happy to walk you through our viability data, our lab sourcing, and what your specific case might benefit from. No pressure, no sales pitch.

Send Me the Information Call (435) 281-2999
$1,999 promotional / $2,499 regular  ·  Same caliber of product, without the broker markup

This information is for general education and is not medical advice. No statements herein have been evaluated by the FDA. Mesenchymal stem cell products described are not approved by the FDA to diagnose, treat, cure, or prevent any disease. Individual results from regenerative therapies vary and outcomes cannot be guaranteed. Patients should consult with a qualified healthcare provider to determine whether a given therapy is appropriate for their specific condition.